IRIX

$1.33+0.00 (+0.00%)

Market OpenAs of Mar 17, 4:53 PM UTC

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.33
Potential Upside
5%
Whystock Fair Value$1.40
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-139.29%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.22

Recent News

Zacks
Jan 2, 2026

Zacks Initiates Coverage of Iridex With Neutral Recommendation

Discover why Zacks initiated coverage of IRIX with a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Learn how global sales momentum and stronger liquidity are balanced against margin pressures and dependency on a key distributor.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Nov 12, 2025

IRIDEX Corp (IRIX) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic Cost Management

IRIDEX Corp (IRIX) reports its fourth consecutive quarter of revenue growth, driven by strong glaucoma product sales and strategic cost-saving measures.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Nov 11, 2025

Iridex: Q3 Earnings Snapshot

MOUNTAIN VIEW, Calif. AP) — Iridex Corp. IRIX) on Tuesday reported a loss of $1.6 million in its third quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
GuruFocus.com
Aug 13, 2025

IRIDEX Corp (IRIX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Cost Challenges

IRIDEX Corp (IRIX) reports a 7% year-over-year revenue increase and continues its cost reduction strategy, despite facing margin pressures and international market challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Aug 12, 2025

Iridex: Q2 Earnings Snapshot

MOUNTAIN VIEW, Calif. AP) — Iridex Corp. IRIX) on Tuesday reported a loss of $994,000 in its second quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.